MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.57
-0.64
-2.64%
After Hours: 23.57 0 0.00% 16:08 01/24 EST
OPEN
24.27
PREV CLOSE
24.21
HIGH
24.27
LOW
23.36
VOLUME
403.27K
TURNOVER
--
52 WEEK HIGH
43.05
52 WEEK LOW
19.35
MARKET CAP
1.24B
P/E (TTM)
11.99
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SUPN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SUPN News

  • FDA accepts Supernus Pharma's SPN-812 application
  • seekingalpha.2d ago
  • The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings
  • Benzinga.2d ago
  • The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings
  • Benzinga.2d ago
  • Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD
  • GlobeNewswire.3d ago

More

Industry

Pharmaceuticals
-1.84%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About SUPN

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
More

Webull offers Supernus Pharmaceuticals Inc (SUPN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.